ECSP10010231A - Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. - Google Patents
Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.Info
- Publication number
- ECSP10010231A ECSP10010231A EC2010010231A ECSP10010231A ECSP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC 2010010231 A EC2010010231 A EC 2010010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A
- Authority
- EC
- Ecuador
- Prior art keywords
- beta
- selective inhibitors
- derivatives
- azaindol
- dehydrogenase type
- Prior art date
Links
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical class C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 abstract 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
Abstract
La presente invención se refiere a derivados 7-azaindol de fórmula I, como inhibidores selectivos de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 (11?-HSD-1) y el uso de dichos compuestos para el tratamiento y prevención del síndrome metabólico, diabetes, resistencia a la insulina, obesidad, trastornos lipídicos, glaucoma, osteoporosis, trastornos cognitivos, ansiedad, depresión, trastornos inmunitarios, hipertensión y otras enfermedades y afecciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291325 | 2007-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010231A true ECSP10010231A (es) | 2010-07-30 |
Family
ID=40445347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010231A ECSP10010231A (es) | 2007-11-05 | 2010-06-03 | Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8470849B2 (es) |
| EP (1) | EP2247589B1 (es) |
| JP (1) | JP5529743B2 (es) |
| KR (1) | KR101624596B1 (es) |
| CN (1) | CN101848910B (es) |
| AU (1) | AU2008324525B2 (es) |
| BR (1) | BRPI0819219B1 (es) |
| CA (1) | CA2704803C (es) |
| CO (1) | CO6270308A2 (es) |
| CY (1) | CY1113645T1 (es) |
| DK (1) | DK2247589T3 (es) |
| EA (1) | EA019707B1 (es) |
| EC (1) | ECSP10010231A (es) |
| ES (1) | ES2400105T3 (es) |
| HR (1) | HRP20130097T1 (es) |
| IL (1) | IL205508A (es) |
| MX (1) | MX2010004815A (es) |
| PL (1) | PL2247589T3 (es) |
| PT (1) | PT2247589E (es) |
| SI (1) | SI2247589T1 (es) |
| UA (1) | UA102379C2 (es) |
| WO (1) | WO2009059666A1 (es) |
| ZA (1) | ZA201004023B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP5899202B2 (ja) * | 2010-04-29 | 2016-04-06 | ザ ユニバーシティ オブ エディンバラ | １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| CN106279154A (zh) * | 2016-08-02 | 2017-01-04 | 叶芳 | 一种7‑氮杂吲哚‑3‑甲醛的制备方法 |
| PH12019502776A1 (en) | 2017-06-30 | 2020-10-26 | Univ California | Compositions and methods for modulating hair growth |
| AU2020407122A1 (en) * | 2019-12-20 | 2022-06-23 | The Regents Of The University Of California | Synthesis of compounds to promote hair growth |
| US20240327400A1 (en) * | 2020-06-30 | 2024-10-03 | The Regents Of The University Of California | Compositions and methods for modulating hair growth |
| US20230365542A1 (en) * | 2020-09-28 | 2023-11-16 | The Regents Of The University Of California | Selective Agonists of 5-HT2A Receptor and Methods of Use |
| CN112390815B (zh) * | 2020-11-03 | 2022-07-26 | 浙江医药股份有限公司新昌制药厂 | 一种Lewis酸脱N-苄基制备d-生物素的制备方法 |
| CN112409353A (zh) * | 2020-11-27 | 2021-02-26 | 苏州艾缇克药物化学有限公司 | 一种7-氮杂吲哚衍生物的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4307073B2 (ja) * | 2000-12-22 | 2009-08-05 | ワイス | ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物 |
| DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| DE10337184A1 (de) * | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
| US7473787B2 (en) * | 2003-10-14 | 2009-01-06 | Pfizer Inc | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| JP2009515833A (ja) * | 2005-10-24 | 2009-04-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ３−ピペリジン−４−イル−インドールｏｒｌ−１受容体モジュレーター |
| US7638062B2 (en) | 2006-07-10 | 2009-12-29 | Cameron International Corporation | Ultra compact cyclonic flotation system |
-
2008
- 2008-10-01 BR BRPI0819219-7A patent/BRPI0819219B1/pt not_active IP Right Cessation
- 2008-10-01 PT PT88027289T patent/PT2247589E/pt unknown
- 2008-10-01 UA UAA201006828A patent/UA102379C2/ru unknown
- 2008-10-01 SI SI200830889T patent/SI2247589T1/sl unknown
- 2008-10-01 US US12/741,254 patent/US8470849B2/en not_active Expired - Fee Related
- 2008-10-01 HR HRP20130097AT patent/HRP20130097T1/hr unknown
- 2008-10-01 MX MX2010004815A patent/MX2010004815A/es active IP Right Grant
- 2008-10-01 KR KR1020107012222A patent/KR101624596B1/ko not_active Expired - Fee Related
- 2008-10-01 PL PL08802728T patent/PL2247589T3/pl unknown
- 2008-10-01 ES ES08802728T patent/ES2400105T3/es active Active
- 2008-10-01 CN CN2008801146395A patent/CN101848910B/zh not_active Expired - Fee Related
- 2008-10-01 AU AU2008324525A patent/AU2008324525B2/en not_active Ceased
- 2008-10-01 JP JP2010531433A patent/JP5529743B2/ja not_active Expired - Fee Related
- 2008-10-01 CA CA2704803A patent/CA2704803C/en active Active
- 2008-10-01 EA EA201000751A patent/EA019707B1/ru not_active IP Right Cessation
- 2008-10-01 DK DK08802728.9T patent/DK2247589T3/da active
- 2008-10-01 EP EP08802728A patent/EP2247589B1/en active Active
- 2008-10-01 WO PCT/EP2008/008309 patent/WO2009059666A1/en not_active Ceased
-
2010
- 2010-05-03 IL IL205508A patent/IL205508A/en active IP Right Grant
- 2010-05-05 CO CO10053458A patent/CO6270308A2/es not_active Application Discontinuation
- 2010-06-03 EC EC2010010231A patent/ECSP10010231A/es unknown
- 2010-06-04 ZA ZA2010/04023A patent/ZA201004023B/en unknown
-
2013
- 2013-02-08 CY CY20131100113T patent/CY1113645T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2247589A1 (en) | 2010-11-10 |
| CA2704803A1 (en) | 2009-05-14 |
| IL205508A (en) | 2013-06-27 |
| MX2010004815A (es) | 2010-05-27 |
| DK2247589T3 (da) | 2013-01-21 |
| IL205508A0 (en) | 2010-12-30 |
| CA2704803C (en) | 2017-04-11 |
| AU2008324525B2 (en) | 2014-09-18 |
| US20100267761A1 (en) | 2010-10-21 |
| JP2011502135A (ja) | 2011-01-20 |
| PT2247589E (pt) | 2013-02-20 |
| CO6270308A2 (es) | 2011-04-20 |
| BRPI0819219A2 (pt) | 2020-08-04 |
| EA019707B1 (ru) | 2014-05-30 |
| WO2009059666A1 (en) | 2009-05-14 |
| KR101624596B1 (ko) | 2016-05-26 |
| CN101848910B (zh) | 2013-12-04 |
| EA201000751A1 (ru) | 2010-12-30 |
| HRP20130097T1 (hr) | 2013-02-28 |
| ES2400105T3 (es) | 2013-04-05 |
| AU2008324525A1 (en) | 2009-05-14 |
| SI2247589T1 (sl) | 2013-03-29 |
| CN101848910A (zh) | 2010-09-29 |
| UA102379C2 (ru) | 2013-07-10 |
| KR20100094500A (ko) | 2010-08-26 |
| US8470849B2 (en) | 2013-06-25 |
| CY1113645T1 (el) | 2016-06-22 |
| BRPI0819219B1 (pt) | 2021-09-21 |
| ZA201004023B (en) | 2011-03-30 |
| EP2247589B1 (en) | 2012-11-21 |
| PL2247589T3 (pl) | 2013-03-29 |
| JP5529743B2 (ja) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010231A (es) | Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. | |
| CO6331305A2 (es) | Nuevos derivados de nip tiazol como inhibidores de la 11-beta- hidroxiesteriode deshidrogenasa-1 | |
| BRPI0619839B8 (pt) | derivados de 2-adamantiluréia, seu método de preparação e seus usos, composição farmacêutica, e kit | |
| BRPI0606256A2 (pt) | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos | |
| ECSP088833A (es) | Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| ECSP13012900A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
| MX347145B (es) | Derivados de adamantilo-acetamida como inhibidores de la enzima tipo i de 11-beta-hidroxiesteroide deshidrogenasa. | |
| CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
| BRPI0606228A2 (pt) | inibidores de enzima 11-beta-hidroxiesteróide desidrogenase tipo 1 | |
| GEP20135793B (en) | Heteroaryls amide derivatives and their use as glucokinase activators | |
| CR11183A (es) | Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1 | |
| ATE556050T1 (de) | Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms | |
| GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
| CR20110255A (es) | Nuevos compuestos 578 | |
| ECSP088839A (es) | Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| MX2010005861A (es) | Agonistas novedosos de los receptores de glucocorticoides. | |
| UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
| UY32778A (es) | Terapia de combinación para el tratamiento de la diabetes | |
| CR20110318A (es) | Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos | |
| UY32312A (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
| MX2011011082A (es) | Derivados de amida y amidina novedosos y usos de los mismos. | |
| UY28774A1 (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes. | |
| CO6321281A2 (es) | Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs) | |
| CO7200248A2 (es) | Derivados de etinilo como moduladores de la actividad de los receptores mglur5 | |
| CR10036A (es) | Procedimientos para la preparación de derivados de ciclopropilamida |